- Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701
- Announced presentation of updated CRB-701 data in HNSCC and cervical cancer at ASCO 2026
- Completed enrollment in 16-week study CANYON-1 study (n=240) of CRB-913 for the treatment of obesity with topline data on track to report this summer
"We’ve continued to build strong momentum with CRB-701 and CRB-913, setting the stage for rapidly approaching inflection points for both the oncology and obesity programs,” said
“Having reached broad alignment with the FDA, we’re on track to start a registrational study for CRB-701 in second-line HNSCC this summer. We’ll report updated data at ASCO 2026 that will provide clear insight into CRB-701's differentiated profile in 2L HNSCC and its upcoming registrational study. We’ll also present updated data in 2L cervical cancer, a patient population with few treatment options. Turning to obesity, we have reached last patient/first visit in our CANYON-1 Phase 1b study and are on schedule to report 16-week, 240-patient data for CRB-913 this summer. CRB-913 represents a unique oral obesity drug with a non-GLP-1 and non-incretin mechanism of action and has the potential for weight loss and long-term weight management. We’re excited about CRB-913's promise to deliver an orthogonal drug class into the obesity treatment landscape.”
Key Corporate and Program Updates
CRB-701 is a next-generation, highly stable Nectin-4 targeting antibody drug conjugate (ADC) being developed to treat HNSCC and cervical cancer. The
- Announced broad alignment with the FDA on the registration path for CRB-701 in HNSCC and cervical cancers and continued interactions with the FDA to finalize the protocols and statistical analysis plans for the registrational studies.
- Anticipated catalysts for CRB-701 in 2026:
- Report monotherapy data from the Phase 1/2 study of CRB-701 in both HNSCC and cervical cancers at the upcoming 2026
American Society of Clinical Oncology (ASCO) annual meeting. Link here for press release with more details. - Initiate a registrational study for CRB-701 in second-line HNSCC this summer.
- Report CRB-701 + Keytruda® combination data in first-line HNSCC patients in early Q1 2027 to support potential further registration-enabling trials.
- Report monotherapy data from the Phase 1/2 study of CRB-701 in both HNSCC and cervical cancers at the upcoming 2026
CRB-913 is a highly peripherally restricted oral CB1 inverse agonist for the treatment of obesity.
- Completed enrollment of last patient and completion of the first clinical visit in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study follows patients over a 12-week treatment period followed by a 4-week safety follow-up and is on track to be completed in the summer of 2026.
- Anticipated catalyst for CRB-913 in 2026:
- Report topline CANYON-1 Phase 1b dose-ranging 16-week study (n=240) in summer 2026.
- Report topline CANYON-1 Phase 1b dose-ranging 16-week study (n=240) in summer 2026.
Financial Results for the Quarter Ended
The Company reported a net loss of approximately
Operating expenses increased by
The Company had
About Corbus
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
INVESTOR CONTACTS:
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com
Managing Director
daniel@lifesciadvisors.com
MEDIA CONTACT:
Founder & Principal
liz@melonecomm.com
---tables to follow---
Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) | ||||||||
| For the Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 19,819 | $ | 15,642 | ||||
| General and administrative | 4,485 | 4,133 | ||||||
| Total operating expenses | 24,304 | 19,775 | ||||||
| Operating loss | (24,304 | ) | (19,775 | ) | ||||
| Other income (expense), net: | ||||||||
| Interest and investment income, net | 1,402 | 1,681 | ||||||
| Other (expense) income, net | (67 | ) | 1,116 | |||||
| Total other income, net | 1,335 | 2,797 | ||||||
| Net loss | $ | (22,969 | ) | $ | (16,978 | ) | ||
| Net loss per share, basic and diluted | $ | (1.23 | ) | $ | (1.39 | ) | ||
| Weighted average number of common shares outstanding, basic and diluted | 18,706,622 | 12,202,092 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (22,969 | ) | $ | (16,978 | ) | ||
| Other comprehensive loss: | ||||||||
| Change in unrealized loss on marketable debt securities | (108 | ) | (58 | ) | ||||
| Total other comprehensive loss | (108 | ) | (58 | ) | ||||
| Total comprehensive loss | $ | (23,077 | ) | $ | (17,036 | ) | ||
Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | ||||||||
(Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,661 | $ | 28,492 | ||||
| Investments | 112,558 | 134,777 | ||||||
| Restricted cash | 385 | 670 | ||||||
| Prepaid expenses and other current assets | 4,962 | 3,015 | ||||||
| Total current assets | 143,566 | 166,954 | ||||||
| Property and equipment, net | 116 | 159 | ||||||
| Operating lease right-of-use assets | 798 | 1,082 | ||||||
| Total assets | $ | 144,480 | $ | 168,195 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 435 | $ | 2,215 | ||||
| Accrued expenses | 16,498 | 16,844 | ||||||
| Operating lease liabilities | 1,205 | 1,633 | ||||||
| Total current liabilities | 18,138 | 20,692 | ||||||
| Total liabilities | 18,138 | 20,692 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, 17,738,870 and 17,611,511 shares issued and outstanding at | 2 | 2 | ||||||
| Additional paid-in capital | 704,900 | 702,984 | ||||||
| Accumulated deficit | (578,399 | ) | (555,430 | ) | ||||
| Accumulated other comprehensive loss | (161 | ) | (53 | ) | ||||
| Total stockholders’ equity | 126,342 | 147,503 | ||||||
| Total liabilities and stockholders’ equity | $ | 144,480 | $ | 168,195 | ||||
